ArticleFrontiers in veterinary science2025
Effect of bluetongue serotype 3 vaccines on probability of viremia and NSAID usage in Dutch dairy cattle herds.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The changing landscape of bluetongue in northern Europe.Journal of medical entomology · 2026Review
- High Seroprevalence of Bluetongue Virus Serotype 3 in Belgian Cattle and Sheep After the 2024 Epidemic.Viruses · 2026Article
- Review
- Bluetongue in the Mediterranean Basin: An Overview of Recent Hotspots and Advances in Vaccine Technologies.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: After the outbreak of bluetongue serotype 3 (BTV3) in The Netherlands in September 2023, three pharmaceutical companies developed inactivated vaccines against this newly emerged serotype in a short period of time, making it possible to start a vaccination campaign just before the start of the new outbreak in 2024. This study describes effectiveness of these vaccines under field conditions in Dutch dairy cattle herds. Materials and methods: Data from 1,114 dairy cattle herds was collected, of which 518 (46.5%) completed the double vaccination scheme and 29 (2,6%) vaccinated once. Results from PCR blood samples that were taken as part of the early warning system were used as a proxy for viremia. As a proxy for morbidity in dairy cattle herds, NSAID usage was used. Results: Herds that fully vaccinated with Bultavo, were less frequently tested for BTV3 and we observed a significant reduction in the probability of detecting bluetongue virus RNA compared to non-vaccinated herds. A significant increase in NSAID usage in the months July, August, September compared to the same period the year before was seen in non-vaccinated herds. Such increase was also seen in vaccinating herds, but a significantly smaller increase was seen for Bultavo vaccinating herds. Discussion: Altogether, we found large differences between the three vaccines in field effectiveness in dairy cattle in 2024 and conclude that Bultavo is the preferable option to prevent clinical signs and disease transmission under these circumstances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.